Scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, collaborating with international researchers, have developed an AI algorithm that performs advanced computational analysis to identify potential therapeutic targets for glioblastoma multiforme and other cancers.
Yale Cancer Center scientists have developed a technology that enables massively parallel DNA substitutions (known as “knock-ins”) into human cells by taking advantage of messenger RNA, a platform now well-known from its use as the COVID vaccine vehicle.
In a study published in Cell Reports Medicine, a team of scientists at Baylor College of Medicine focused on the molecular pathways metastatic cancer cells use and identified four cancer subtypes according to the main genes expressed. The findings unveiled potential vulnerabilities of each subtype that have relevant implications for therapy.
Researchers at Baylor College of Medicine, the University of Michigan, and collaborating institutions working with animal models of graft-versus-host disease reported in Immunity that alterations in the gut microbiome are connected to an increase in the oxygen levels in the intestine that follows immune-mediated intestinal damage. Pharmacologically reducing intestinal oxygen levels alleviated the microbial imbalance and reduced the severity of the intestinal disease.
To mark World Cancer Day, researchers from the International Agency for Research on Cancer in collaboration with the Lalla Salma Foundation for Cancer Prevention and Treatment (Morocco) published a report that provides solutions to overcoming some of the common system-level barriers to implementation of cervical cancer screening, which are faced in many countries in sub-Saharan Africa.
Investigators from Rutgers Cancer Institute of New Jersey found that a higher risk of mortality in Black breast cancer survivors is associated with a history of cigarette smoking along with regular alcohol consumption at the time of diagnosis.
A study, published in The Lancet Oncology, reports large international differences in survival among patients diagnosed with 15 common cancer types in Asia, Africa, and Latin America and the Caribbean.
TRANSCEND CLL 004, a phase I/II, open-label, single-arm, multicenter study evaluating Breyanzi (lisocabtagene maraleucel) in adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, met its primary endpoint of complete response rate compared to historical control in the prespecified subset of patients with R/R CLL that was refractory to a BTK inhibitor and pretreated with a BCL-2 inhibitor.
A multi-institutional team led by scientists from the Medical College of Wisconsin Cancer Center has discovered PD-L2 as a therapy-relevant marker to identify patients with estrogen receptor-positive breast cancer who may benefit from new immunotherapies.
A new clinical and preclinical study from UCLA Jonsson Comprehensive Cancer Center identifies the DNA roots of resistance to targeted cancer therapy. Results are published online ahead of print in Cancer Discovery, a journal of the American Association for Cancer Research.
